Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall

biote Corp.

2026-Q1 EPS reported $0.06 revenue$44,935,000

Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.
Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.
Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.
Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.
Management expects return to procedure growth in second half of 2026 after recall impact.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

biote Corp. reported the first quarter ended March 31, 2026 results: revenue Revenue of $44.9 million, net income Net income of $2.7 million, EPS diluted earnings per share attributable to biote Corp. stockholders of $0.06.

Period: the first quarter ended March 31, 2026
Revenue: Revenue of $44.9 million
Net income: Net income of $2.7 million
EPS: diluted earnings per share attributable to biote Corp. stockholders of $0.06
Result: reported results

Exact text from the filing

Results Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights • Revenue of $44.9 million • Gross profit margin of 68.9% • Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-26-208965

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.